LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma (Canbiome2)

A Phase II Randomized Trial of LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Patients With Advanced Melanoma

This study is being done to answer the following question: Can the chance of melanoma growing or spreading be lowered by receiving a treatment called LND101 for Fecal Microbiota Transplant (FMT) in addition to the usual immunotherapy treatment called Immune Checkpoint Blockade (ICB)? FMT treatment changes the bacteria in your gut called the microbiome.

Study Overview

• Status: Recruiting
• Conditions: Melanoma
• Intervention / Treatment: Drug: Standard of Care Immune Checkpoint Blockade; Drug: LND101

Detailed Description

We are doing this study because we want to find out if this approach (adding LND101 FMT to ICB) is better or worse than the usual approach (ICB only) for advanced melanoma. The usual approach is defined as care most people get for advanced melanoma.

The usual approach for patients who are not in a study is treatment with immunotherapy drugs called immune checkpoint blockade (ICB) drugs. Immunotherapy works by activating the immune system to target the cancer. This may help to slow down the growth of cancer and may cause cancer cells to die.

• Study Type: Interventional
• Enrollment (Estimated): 128
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Janet Dancey; Phone Number: 613-533-6430; Email: jdancey@ctg.queensu.cca

Study Locations

• Canada
  • British Columbia
    • Abbotsford British Columbia, British Columbia, Canada, V2S 0C2
      • Recruiting
      • BCCA - Abbotsford
      • Contact: Thao Nguyen; Phone Number: 604 851-4707
    • Surrey, British Columbia, Canada, V3V 1Z2
      • Recruiting
      • BCCA - Surrey
      • Contact: Christopher Lee; Phone Number: 604 930-4017
    • Vancouver, British Columbia, Canada, V5Z 4E6
      • Recruiting
      • BCCA - Vancouver
      • Contact: Kerry J. Savage; Phone Number: 2641 604 877-6000
  • Ontario
    • Hamilton, Ontario, Canada, L8V 5C2
      • Recruiting
      • Juravinski Cancer Centre at Hamilton Health Sciences
      • Contact: Baskoro (Adi) Kartolo; Phone Number: 905 387-9495
    • London, Ontario, Canada, N6A 5W9
      • Recruiting
      • London Health Sciences Centre Research Inc.
      • Contact: John Lenehan; Phone Number: 519 685-8640
    • Newmarket, Ontario, Canada, L3Y 2P9
      • Recruiting
      • Stronach Regional Health Centre at Southlake
      • Contact: Shaqil Kassam; Phone Number: 905 895-4521
    • Ottawa, Ontario, Canada, K1H 8L6
      • Recruiting
      • Ottawa Hospital Research Institute
      • Contact: Michael Ong; Phone Number: 75051 613 737-7700
    • Toronto, Ontario, Canada, M5G 2M9
      • Recruiting
      • University Health Network
      • Contact: Marcus Butler; Phone Number: 5485 416 946-4501
    • Toronto, Ontario, Canada, M4N 3M5
      • Recruiting
      • Odette Cancer Centre
      • Contact: Rossanna Pezo-Martin; Phone Number: 416 480-4757
  • Quebec
    • Greenfield Park, Quebec, Canada, J4V 2H1
      • Recruiting
      • Centre Integre de Sante et de Services Sociaux
      • Contact: Virginie Vallee-Guignard; Phone Number: 450 466-5000
    • Montreal, Quebec, Canada, H3T 1E2
      • Recruiting
      • The Jewish General Hospital
      • Contact: Wilson Miller; Phone Number: 4365 514 340-8222
    • Montreal, Quebec, Canada, H2X 3E4
      • Recruiting
      • CHUM-Centre Hospitalier de l'Universite de Montreal
      • Contact: Rahima Jamal; Phone Number: 514 890-8444
    • Québec, Quebec, Canada, G1R 2J6
      • Recruiting
      • Hotel-Dieu de Quebec
      • Contact: Chloe Beland; Phone Number: 67322 418 525-4444
    • Trois-Rivières, Quebec, Canada, G8Z 3R9
      • Recruiting
      • Centre hospitalier regional de Trois-Rivieres
      • Contact: Anouk Tremblay; Phone Number: 63337 819 697-3333

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participants must have a confirmed histological diagnosis of cutaneous melanoma or melanoma of unknown primary.
• Participants must have stage IV or advanced unresectable disease.
• No prior ICB treatment for advanced unresectable or metastatic disease. Participants may have received adjuvant or neoadjuvant ICB if last dose was given ≥ 6 months prior to enrollment
• Prior targeted therapy with BRAF/MEK inhibition in the adjuvant or advanced / metastatic setting is permitted if at least 2 weeks have elapsed between the last dose and study enrollment. Participants must have recovered to ≤ grade 1 from all toxicity related to BRAF/MEK inhibition
• Prior radiation therapy is permitted if at least 7 days have elapsed between the last fraction and study enrollment. Participants must have recovered to ≤ grade 1 from all toxicity related to prior radiotherapy.
• Previous major surgery is permitted provided that surgery occurred ≥ 14 days prior to participant enrollment and that wound healing has occurred.
• Participants must have measurable disease as per RECIST 1.1/ iRECIST.
• Participants must be at least 18 years of age.
• Participants must have an ECOG performance status of 0, 1, or 2.
• The participant's standard-of-care ICB regimen must be selected prior to enrollment and must stay the same, regardless of arm assignment, post-enrollment
• Participants must demonstrate adequate organ function Participants must be able to ingest capsules.
• Participants must consent to provision of samples of blood and stool for correlative marker analysis.
• Participants must consent to provision of, and investigator must agree to submit, a representative archival formalin fixed paraffin block of tumour tissue for correlative analyses when tumour tissue is available.
• Participants must have access to provincially-funded standard-of-care ICB treatment.
• Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form prior to enrollment in the trial to document their willingness to participate.
• Participants must be accessible for treatment and follow-up. Investigators must assure themselves the participants randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
• Protocol ICB treatment must begin within 14 calendar days after participant enrollment.
• Participants of childbearing potential must have agreed to use a highly effective contraceptive method.

Exclusion Criteria:

• Participants with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.
• Participants who have received antibiotics within 14 days of enrollment.
• Participants with systemic prednisone use > 10mg per day or equivalent dose.
• Participants with concurrent treatment with other anti-cancer therapy.
• Participants that have received live attenuated vaccination administered within 30 days prior to randomization. Note: Seasonal vaccines for influenza and COVID-19 are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and not allowed.
• For participants with history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
• Participants with absolute contraindications to FMT including: a) Toxic megacolon; b) Inflammatory bowel disease; c) Severe dietary allergies
• Participants with hypersensitivity to PegLyte®

• Participants with symptomatic brain metastases unless brain lesions are shown to be stable, according to the following definitions:

  1. without evidence of progression for at least four weeks prior to randomization and have no evidence of new or enlarging brain metastases; or
  2. treated with surgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases; or
  3. treated with stereotactic radiosurgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.
  4. asymptomatic or minimally symptomatic active metastases, with controlled steriod use and no imminent CNS complications.
• Participants with leptomeningeal disease.
• Participants with any uncontrolled autoimmune disease that requires active immunosuppressive agents.
• Participants who are solid organ transplantation recipients or likely to receive solid organ transplants in the future.
• Participants living with HIV.
• Participants with active infection. Participants may be eligible following recovery. Participants requiring antibiotics require 2-week washout period prior to enrollment.
• Participants that are pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Standard-of-care ICB; Assigned single agent or combination ICB treatment	Drug: Standard of Care Immune Checkpoint Blockade; Any ICB (single agent or combination) may be used that is commercially available, Health Canada-approved and publically funded for the treatment of participants with advanced, unresectable or metastatic melanoma. The treatment decision for choice of ICB regimen will be made prior to randomization and cannot be changed after enrollment
Experimental: LND101 for FMT + Standard-of-care ICB; Bowel preparation; LND101(single-dose); Assigned single agent or combination ICB treatment.	Drug: Standard of Care Immune Checkpoint Blockade; Any ICB (single agent or combination) may be used that is commercially available, Health Canada-approved and publically funded for the treatment of participants with advanced, unresectable or metastatic melanoma. The treatment decision for choice of ICB regimen will be made prior to randomization and cannot be changed after enrollment; Drug: LND101; Approximately 40 capsules (total of 80-100g of processed fecal material) taken by mouth 7 days prior to the ICG agent(s) administered following bowel preparation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Progression-free Survival	4 years

Secondary Outcome Measures

Outcome Measure	Time Frame
Overall Survival	4 years
Objective Response Rate	4 years
Number and severity of adverse events assessed with CTCAE version 5.0	4 years

Collaborators and Investigators

• Sponsor: Canadian Cancer Trials Group
• Collaborators: Canadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS); Weston Family Foundation
• Investigators: Study Chair: Arielle Elkrief, CHUM-Centre Hospitalier de ''Universite de Montreal, Montreal, QC Canada; Study Chair: John Lenehan, London Regional Cancer Program, London, ON Canada

Publications and helpful links

General Publications

• Hadi DK, Baines KJ, Jabbarizadeh B, Miller WH, Jamal R, Ernst S, Logan D, Belanger K, Esfahani K, Elkrief A, Parvathy SN, Silverman MS, Routy B, Maleki Vareki S, Lenehan JG. Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial. J Immunother Cancer. 2025 Aug 4;13(8):e012659. doi: 10.1136/jitc-2025-012659.

Study record dates

Study Major Dates

• Study Start (Actual): April 7, 2025
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2029

Study Registration Dates

• First Submitted: September 30, 2024
• First Submitted That Met QC Criteria: September 30, 2024
• First Posted (Actual): October 2, 2024

Study Record Updates

• Last Update Posted (Actual): May 12, 2026
• Last Update Submitted That Met QC Criteria: May 11, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Skin Diseases; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Nevi and Melanomas; Skin Neoplasms; Skin and Connective Tissue Diseases; Melanoma; Antineoplastic Agents, Immunological; Antineoplastic Agents; Molecular Mechanisms of Pharmacological Action; Immune Checkpoint Inhibitors
• Other Study ID Numbers: ME17; Canbiome2 (Other Identifier: CCTG)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: As per CCTG policies.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No